GlassScriptPhysician profile
Dan Marshall Mcentire
NPI 1417489485
$2,091.50
in general payments reported to CMS, 2019-2025
15 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $274 · 2023: $131 · 2024: $447 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Travel and Lodging: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.47 |
| Travel and Lodging | $398.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $792.16 | 2022-2025 | Overstitch Nxt Endoscopic Suturing System, X-Tack Endoscopic Helix Tacking System, Resolution 360 Clip |
| Abbvie INC. | $511.48 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.78 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Steris Corporation | $117.12 | 2023 | |
| Madrigal Pharmaceuticals | $94.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $79.01 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Ipsen Biopharmaceuticals, INC | $67.99 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $60.41 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $21.52 | 2025 | Dupixent |
| Ardelyx, INC. | $18.39 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $16.32 | 2024 | |
| Pfizer INC. | $15.74 | 2025 | |
| Conmed Corporation | $15.15 | 2024 | Conmed Generators, Conmed Biliary, Conmed Dilation |
| Braintree Laboratories, INC. | $14.07 | 2025 | Suflave |
| Merit Medical Systems INC | $11.12 | 2024 | Endomaxx Stent and Delivery System, Alimaxx-Esophageal Stent/Delivery System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Mcentire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.